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Telomerase, a stable complex of telomerase reverse transcriptase (TERT) and
template RNA (TERC), is responsible for telomere maintenance. During purification
trials of recombinant human telomerase of the two components reconstituted in
insect cells, we identified two complexes of human telomerase of molecular masses
680 and 380kDa, both of which retain telomerase activity in vitro. We show here that
the former complex does not include Hsp90 (heat shock protein 90) and its
telomerase activity is resistant to Hsp90 inhibitors, whereas the latter contains
Hsp90 and its telomerase activity is sensitive to Hsp90 inhibitors. N-terminal of
FLAG-hTERT in the former is exposed, as this complex was efficiently purified with
anti-FLAG M2 affinity resin. We also identified two different telomerase complexes in
HeLa cells, in addition to ectopically expressed hTERT. Most of endogenous hTERT
and FLAG-hTERT was detected around 680kDa. These two complexes in HeLa cells
have the same properties as their respective reconstituted telomerases. The unstable
property of the telomerase complex with Hsp90, especially in the presence of Hsp90
inhibitors, was due to proteasome-mediated degradation of hTERT, since proteasome
inhibitors prevented hTERT degradation in vivo. To our knowledge, this is the first
demonstration of two distinct active complexes of human telomerase ectopically
expressed in insect and mammalian cells.
Key words: GA, Hsp90, hTERC, hTERT.
Abbreviations: GA, geldanamycin; Hsp90, heat shock protein 90; hTERC, human telomerase RNA
component; hTERT, human telomerase reverse transcriptase subunit; TRAP, telomere repeat amplification
protocol.
Telomeres are physical ends of eukaryotic chromosomes,
which consist of long tandem repeats (TTAGGG), and are
responsible for maintaining chromosomal stability and
integrity (1, 2). Telomerase is a ribonucleoprotein (RNP)
composed of human telomerase reverse transcriptase
(hTERT), the catalytic subunit, and its template RNA
(hTERC) (2–5). As direct evidence that telomere erosion
plays a major role in cellular senescence, ectopic expression
of hTERT in normal human cells with endogenous hTERC
resulted in activation of telomerase, stabilization of
telomere lengths and extension of cellular life span (6, 7).
The homeostasis of mammalian telomeres is regulated
by a number of telomere-binding proteins. These proteins
form a physical complex of molecular mass 550–1000 kDa
(8–10). Among these proteins, TRF1 and TRF2 directly
bind double-stranded telomere DNA and interact with a
number of proteins to maintain telomere length and
structure (11, 12).
hTERT is the rate-limiting factor for telomerase
activity both biologically and biochemically (6, 13–16).
Although telomerase activity is regulated by hTERT gene
expression (17), it is also regulated post-translationally.
Post-translational modification of telomerase may also
involve the interaction of hTERT with telomerase-
associated proteins, chaperones and polypeptide
modifiers (18, 19). Heat shock protein 90 (Hsp90),
a molecular chaperone, has been reported to be
functionally associated with hTERT, and both Hsp90
and p23 are required for efficient telomerase assembly
in vitro and in vivo, although both of these proteins, as
well as other chaperones, are associated with hTERT in
its unassembled or inactive form (20, 21). The Hsp90
inhibitor, geldanamycin (GA), has been shown to prevent
the assembly of active telomerase, as well as to promote
ubiquitination and the proteasome-mediated degradation
of hTERT (20, 22). These reports clearly demonstrate
the involvement of Hsp90 in telomerase assembly and
function.
We previously identified GA-resistant telomerase
activity using in vitro reconstituted telomerase with
partially purified FLAG-hTERT expressed in insect cells
and in vitro transcribed hTERC (13). We further purified
the recombinant FLAG-hTERT and found that its
in vitro telomerase activity was reduced as it was
purified (data not shown). We therefore attempted to
express recombinant telomerase by reconstituting
hTERT and hTERC in insect cells.
Here we report the properties of reconstituted
telomerase in the lysate of insect cells. We found that
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this activity could be separated into two different
complexes, of molecular masses 680 (peak I) and
380 kDa (peak II), using biochemical fractionation meth-
ods. We also detected similar complexes, of approximate
molecular masses 680 and 400 kDa, in the lysates
of HeLa cells and HeLa cells stably expressing
FLAG-hTERT. The telomerase activity of the former
complex was resistant to Hsp90 inhibitors, whereas
the activity of the latter complex was sensitive to
Hsp90 inhibitors. To our knowledge, this is the first
demonstration of two distinct active complexes of
human telomerase ectopically expressed in insect and
mammalian cells.
EXPERIMENTAL PROCEDURES
Baculovirus Expression Vectors—The FLAG-hTERT
baculovirus expression vector, pBKM-FLAG-hTERT, has
been described (13, 23). The hTERC cDNA was prepared
by PCR using pGRN164 as a template with the primer
set, hTERCFor, which contains artificial NcoI site, and
hTERCRev, which contains artificial BamHI site. The
50 processing ribozyme cDNA was prepared by annealing
of following oligos: RibFor (50-GGATCCGTCGACGGATC
TAGATCCGTCCTGATGAGTCCGTGAGGACGAAACGG
ATCC-30), and RibRev (50-GGATCCGTTTCGTCCTCACG
GACTCATCAGGACGGATCTAGATCCGTCGACGGATC
C-30), each of which contains a BamHI site. SV40 polyA
signalling sequence was prepared by PCR using
pNKZ-FLAG-hTERT as a template with the primer set,
SVFor, which contains artificial BamHI site, and SVRev,
which contains artificial BglII site. The hTERC-PolyA
baculovirus expression vector, pBKM-hTERC-PolyA, was
constructed by inserting the NcoI-BamHI fragment of
hTERC cDNA and the BamHI-BglII fragment of the
SV40 polyA cDNA into the EcoRV and BglII sites of the
pVL1393 baculovirus transfer vector. The hTERC-Rib
baculovirus expression vector, pBKM-hTERC-Rib,
was constructed by inserting the NcoI-BamHI fragment
of hTERC cDNA, the BamHI-BamHI fragment of
50 processing ribozyme cDNA and the BamHI-BglII
fragment of SV40 polyA cDNA into the EcoRV and
BglII sites of the pVL1393 baculovirus transfer vector.
Insect Cell Lines and Generation of Recombinant
Baculoviruses—Sf9 and High5 insect cell lines were
cultured as described, and recombinant baculoviruses
were prepared as described (13, 23). High titre suspen-
sions of BVKM-FLAG-hTERT, BVKM-hTERC-PolyA and
BVKM-hTERC-Rib (41.0 107 plaque-forming units/ml)
were used for infection of High5 cells.
Plasmid Construction—The hTERC-Rib phagemid
expression vector pGRN-hTERC-Rib was constructed by
inserting the BamHI-BamHI fragment of 50 processing
ribozyme cDNA into the BamHI site of the pGRN164
phagemid vector. FLAG-GST cDNA was prepared by
PCR using pNKZ-GST as a template with the primer set,
FLAGFor, which contains artificial FbaI-FLAG-EcoRI
sites, and FLAGRev, which contains artificial XhoI-SalI
sites. The FLAG-GST retrovirus expression vector
pBabe-puro-FLAG-GST was constructed by inserting
the FbaI-XhoI fragment of FLAG-GST cDNA into the
BamHI-SalI sites of the pBabe-puro vector. The GST
cDNA of pBabe-puro-FLAG-GST was replaced by the
EcoRI-SalI fragment containing hTERT cDNA resulting
in retrovirus delivery vector, pBabe-puro-FLAG-hTERT.
Mammalian Cell Lines and Retrovirus Delivery—HeLa
(human carcinoma of cervix) and 293T cells (human
kidney cell lines) were cultured by standard methods
in Dulbecco’s modified Eagle’s medium (Invitrogen)
supplemented with 10% fetal calf serum (FCS; CELLect
R GOLD). Recombinant retrovirus packaging, infection
and selection of FLAG-hTERT expressing stable
transformations of HeLa cells were performed essentially
as described (24).
Partial Purification of in vivo Reconstituted
Telomerase Complex from Insect Cells by Anti-FLAG
M2 Affinity Resin—For expression of in vivo
reconstituted telomerase, High5 cells were co-infected
with both BVKM-FLAG-hTERT and BVKM-hTERC-Rib
(or BVKM-hTERC-PolyA) at a multiplicity of infection
(MOI) ratio of 2.0 : 4.0. The cells were cultured for 5 days
at 278C, scraped off the plates and centrifuged at
2500 g for 10 min. A total of 5 107 High5 cells were
suspended in 5 ml of buffer A [20 mM Tris–HCl (pH 7.5),
200 mM NaCl, 10 mM 2-mercaptoethanol, 20% glycerol,
0.1% Triton, 1 mM dithiothreitol (DTT), 1 mM
phenylmethylsulfonyl fluoride (PMSF), 10 mM leupeptin
and 10 mM aprotinin] and the suspension was sonicated
three times for 10 s each. The lysate was centrifuged for
10 min at 10,000 g. The supernatant (S1) was removed
and detergent concentration of S1 was adjusted to 0.5%
by 20% Triton-X100 (S2). S2 was mixed with 500 ml of
50% slurry of anti-FLAG M2 affinity resin (Sigma), and
rotated for 4 h at 48C. After 1 min centrifugation at
4500 g, the supernatant was removed, and the resin with
bound proteins was washed three times with buffer A.
500ml of buffer B (buffer A containing, 100mg/ml
FLAG peptide) was added to washed resin and the
mixture was rotated for 30 min at 48C. After 1 min
centrifugation at 4500 g, the supernatant (M2-bound
fraction 1) was recovered. Moreover, 500 ml of buffer B
was added to washed resin and the mixture was rotated
for 30 min at 48C. After 1 min centrifugation at 4500 g,
the supernatant (M2-bound fraction 2) was recovered.
M2-bound fractions 1 and 2 were mixed (M2-bound
fractions). FLAG-tagged hTERT protein was quantified
by SDS–PAGE on 8% polyacrylamide gels, and gels were
stained with Coomassie Brilliant Blue (CBB).
Northern Blot Analysis—10 mg of total RNA from
each infected High5 cells were run for each lanes,
electrophoresed on a 1.0% agarose gel containing 2.2 M
formaldehyde and transferred to Hybond-Nþ membrane
(Amersham Biosciences), crosslinked by UV for 2 min
and subjected for hybridization. Membrane was
probed with 32P-labelled in vitro transcribed hTERC
(full-length). Hybridization was performed according
to the manufacturer’s recommendations (Amersham
Biosciences), and the autoradiograms were scanned on
a BAS2000 bio-imaging analyser (FUJIX).
Preparation of Cell Lysates, Immunoprecipitation—
Cells were harvested, washed with PBS() and sonicated
in buffer A. The lysate of 5 106 cells was diluted 10-fold
in buffer A and incubated at 48C for 3 h with 10 ml of
GammaBind G resin containing pre-bound anti-FLAG
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M2 (Sigma), followed by three washes with buffer A.
The bound proteins were separated by SDS–PAGE and
visualized by western blotting.
Fractionation of Cell Lysates—M2-bound fractions
or the lysate of 5 107 cells were fractionated on
HiLoad 16/60 Superdex 200 pg gel filtration columns
(Amersham Biosciences) in running buffer A without
protein inhibitors. The resulting fractions were resolved
by SDS–PAGE and probed with various antibodies. For
the calibration of the column, the high molecular weight
calibration kit from Amersham Biosciences was used.
Antibodies and Western Blot Analysis—For western
blot analysis, the total cell lysate and their fractions from
gel filtration column were separated by SDS–PAGE and
transferred to nitrocellulose membrane and probed with
anti-FLAG M2, anti-Hsp 90a/b (Santa Cruz
Biotechnology) or anti-TERT 2C4 (Novus Biologicals,
Inc.) primary antibodies, followed by incubation with
horseradish peroxidase conjugated goat anti-mouse
IgG secondary antibody (Amersham Biosciences)
for anti-FLAG M2 and anti-Hsp 90a/b antibodies,
or horseradish peroxidase conjugated goat anti-mouse
IgM secondary antibody (Pierce) for anti-TERT 2C4
antibody.
Telomerase Activity Assays—Telomerase activity was
measured by two different methods. (i) TRAP assay, a
polymerase chain reaction-based telomere repeat ampli-
fication protocol assay (TRAP assay), was carried out
with TRAPEZE kit (Intergen Co. Ltd) according to the
manufacturer’s protocol. Each reaction product was
amplified in the presence of a 36-bp internal telomerase
assay standard (ITAS). The polymerase chain reaction
products were fractionated by electrophoresis on a 10%
polyacrylamide gel and then visualized by staining with
SYBR Green I (Molecular Probes Co. Ltd). (ii) TRAP
enzymelinked immunosorbent assay (ELISA), telomerase
activity was quantitatively measured using a TRAPEZE
ELISA telomerase detection kit (Intergen Co. Ltd)
according to the manufacturer’s protocol.
Real-time Quantitative RT-PCR—Real-time quantita-
tive RT-PCR was performed for hTERC using the ABI
Prism 7900HT Sequence Detection System (Applied
Biosystems). Primers and the TaqMan probe for hTERC
were designed using the primer design software Primer
ExpressTM (Applied Biosystems). The forward
primer for hTERC was 50-GGTGGTGGCCATTTTTT
GTC-30. The reverse primer for hTERC was
50-CTAGAATGAACGGTGGAAGGC-30. The TaqMan
probe for hTERC was 50-CGCGCTGTTTTTC
TCGCTGACTTTC-30 (25). The probe was labelled
with a reporter fluorescent dye (6-carboxy-fluorescein)
at the 50 end and a quencher fluorescent dye (6-carboxy-
tetramethyl-rhodamine) at the 30 end. The PCR
conditions were 1 cycle at 508C for 2 min and 958C
for 10 min, followed by 40 cycles at 958C for 15 s and
608C for 1 min.
RESULTS
Partial Purification Trials of in vivo Reconstituted
Telomerase Complex from Insect Cells by M2 Affinity
Resin—We previously reported that telomerase activity
reconstituted in vitro using partially purified FLAG-
hTERT expressed in insect cells and in vitro transcribed
hTERC was resistant to GA (13). During further
purification of the recombinant FLAG-hTERT, we found
that the highly purified FLAG-hTERT preparations
reconstituted lower telomerase activity in vitro (data
not shown). The peak fractions of FLAG-hTERT from
heparin cellulose column chromatography, in which
FLAG-hTERT was estimated to be 70%, failed
to reconstitute any telomerase activity in vitro in
the presence of hTERC. We therefore attempted to
co-express FLAG-hTERT and hTERC in insect cells and
to purify in vivo reconstituted telomerase. For this
purpose, we constructed baculovirus delivery plasmids
of hTERC-expression baculovirus. To mimic as close as
possible the intrinsic transcription pathway for TERC,
we chose Polyhedrin promoter and a polyadenilation
(polyA) tailing to transcribe hTERC in insect cells
(BVKM-hTERC-PolyA). Once hTERC transcription is
successfully initiated and terminated, we prefer to
eliminate the polyA tail, since it was possible that the
factors complexed with the polyA tail may interfere with
high-grade purification and further biochemical studies.
Additionally, there is no report showing that polyA-tailed
hTERC exists in human cells. We attempted to remove
the polyA tail by splicing in vivo using a self-cleaving
hammer-head ribozyme, or by cleavage in vitro using
targeting ribozyme. The polyA tail could not be cleaved
in vitro using targeting ribozyme. To ensure function
of self-cleaving hammerhead ribozyme, 50-processing
ribozyme was inserted into the pGRN164 phagemid
vector after the hTERC coding sequence and 100 bp
upstream to the digestion site that was used to linearize
the vector to prepare a template for in vitro transcrip-
tion. In this case, two bands instead of one appear on a
gel electrophoresis as a product of in vitro transcription
due to ribozyme self-splicing (Fig. 1A, compare lanes
2 and 3). The hTERC origin of the resulting bands was
identified by northern blot with hTERC probe (Fig. 1A,
lanes 4–6). Having confirmed the effectiveness of
50-processing ribozyme, we constructed a recombinant
baculovirus producing hTERC with a self-cleaving ribo-
zyme at the 50-end. The schematic presentation of
baculovirus transfer vector expressing hTERC under
the control of polyhedrin promoter is shown in Fig. 1B.
SV40 polyA signal was inserted downstream of hTERC
coding sequence. The 50-processing ribozyme was
inserted into the baculovirus transfer vector after the
hTERC coding sequence and before SV40 polyA signal
(pBKM-hTERC-Rib). High5 cells were infected
with BVKM-FLAG-hTERT and BVKM-hTERC-PolyA or
BVKM-hTERC-Rib. Expression of the intact hTERC was
detected by northern blot only when the hTERC- and
FLAG-hTERT expression viruses were co-infected
and the size of hTERC produced by BVKM-hTERC-Rib
was similar to that of in vitro transcribed hTERC
(Fig. 1C, lanes 1 and 3). However, hTERC produced by
BVKM-hTERC-PolyA had larger size due to the
polyA incorporation (Fig. 1C, lane 2). The hTERC RNA
could not be detected by northern blotting,
when hTERC-expression virus alone, either BVKM-
hTERC-PolyA or BVKM-hTERC-Rib, was infected,
suggesting that hTERC RNA might be degraded in
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Fig. 1. Partial purification trials of in vivo reconstituted
telomerase complex in insect cells by M2 affinity resin.
(A) pGRN164 and pGRN-Rib were linearized by digestion with
PvuI and subjected to in vitro transcription (pGRN164 and pGRN-
Rib, respectively). pGRN164 was linearized by digestion with FspI
and subjected to in vitro transcription (in vitro hTERC). In vitro
transcribed RNAs were fractionated on denaturing agarose-gel
electrophoresis and detected by either EtBr (left panel) or northern
blot with hTERC probe (right panel). Lanes 1 and 4, in vitro
hTERC; lanes 2 and 5, pGRN164; lanes 3 and 6, pGRN-Rib.
(B) Schematic presentation of baculovirus transfer vector expres-
sing hTERC under the control of the polyhedrin promoter. The 50
processing ribozyme was inserted between hTERC coding sequence
and the SV 40 polyadenilation (PolyA) signal. (C) Total RNAs
isolated from High5 cells infected with both BVKM-FLAG-hTERT
(FLAG-hTERT) and BVKM-hTERC-PolyA (hTERC-PolyA) or
BVKM-hTERC-Rib (hTERC-Rib) were assayed by northern blot-
ting with 32P-labelled hTERC as a probe. Lane 1, hTERC-Rib;
Lane 2, hTERC-PolyA; Lane 3, in vitro hTERC. (D) High5 cells
were infected with recombinant baculoviruses BVKM-FLAG-
hTERT (FLAG-hTERT) and BVKM-hTERC-Rib (hTERC-Rib) at
MOI ratio of 2.0 : 4.0, and lysate of infected cells were prepared and
subjected to affinity chromatography with anti-FLAG M2 resin
(see ‘EXPERIMENTAL PROCEDURES’). Each sample was separated by 8%
SDS–PAGE, and gels were stained with CBB and subjected to
western blot analysis with anti-FLAG M2 antibody. Lanes 2 and 8,
total lysate of the infected High5 cells; lanes 3 and 9, supernatant
S1; lanes 4 and 10, M2 unbound fractions; lanes 5 and 11, anti-
FLAG M2 resin; lanes 6 and 12, M2-bound fraction 1; lanes 7 and
13, M2-bound fraction 2. The arrows indicate FLAG-hTERT.
(E) Two microlitres of M2-bound fractions and HeLa cell lysate
were subjected to TRAP assay. Bound fractions were treated by
incubating at 858C for 10 min, or treated with 100mg/ml RNase
A at 308C for 15 min. Lane1, HeLa; lane 2, M2-bound fraction
(no treatment); lane 3, M2-bound fraction treated by heat; lane 4,
M2-bound fraction by RNase. ITAS represents the internal
telomerase assay standard. (F) M2 bound fractions were fractio-
nated on HiLoad 16/60 Superdex 200 pg gel filtration columns in
running buffer containing 200 mM NaCl and 0.1% Triton-X100.
The molecular sieving peak corresponded to approximate molecu-
lar masses of 680 kDa. The fractions were separated by 8%
SDS–PAGE and subjected to western blot analysis using anti-
FLAG M2 or anti-Hsp90 antibodies. Lane 1, as ‘I’ (¼ input) is
M2-bound fractions; lane 2, fraction No. A5; lane 3, fraction No.
A6; lane 4, fraction No. A7; lane 5, fraction No. A8; lane 6, fraction
No. A9; lane 7, fraction No. A10; lane 8, fraction No. B11; lane 9,
fraction No. B12; lane 10, fraction No. C11; and lane 11, as control,
HeLa cell lysate. The arrows indicate FLAG-hTERT. Relative
telomerase activity of fractions was measured by TRAP ELISA.
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insect cells in the absence of hTERT (data not shown).
Insect cell lysate expressing FLAG-hTERT and hTERC-
Rib was fractionated using anti-FLAG M2 resin. Most of
FLAG-hTERT could be eluted from anti-FLAG M2 resin
with the buffer containing FLAG peptide (see
‘EXPERIMENTAL PROCEDURES’ and Fig. 1D). We found that
the fractionation behaviour of two types of telomerase
with hTERC-PolyA and hTERC-Rib expressed in insect
cells was almost identical, except the telomerase consist-
ing of FLAG-hTERT and hTERC-PolyA bound more
efficiently to polyU resin than did the telomerase
consisting of FLAG-hTERT and hTERC-Rib (data not
shown). The partially purified in vivo reconstituted
telomerase complex exhibited comparable telomerase
activity to that of endogenous telomerase from HeLa
cells detected by the TRAP assay (Fig. 1E, lanes 1 and 4).
This activity was abolished by heat treatment or RNase
treatment (Fig. 1E, lanes 2 and 3). Since the expression
level, fractionation behaviour and activity of the two
types of telomerase reconstituted in vivo were almost
identical, we assayed the properties of recombinant
telomerase consisting of FLAG-hTERT and hTERC-Rib.
The expression level of FLAG-hTERT in High5 cells
infected with BVKM-FLAG-hTERT and BVKM-hTERC-
Rib at MOI of 2.0 and 4.0 (see ‘EXPERIMENTAL
PROCEDURES’), respectively, was higher than those
obtained from other combinations of MOI (data not
shown). For the purpose of additional steps towards
higher purity, M2 bound fractions of insect cells expres-
sing FLAG-hTERT and hTERC-Rib was subjected to gel
filtration on Superdex 200 pg column. The fractions were
assayed for telomerase activity and the elution profile
was compared with those of the marker proteins of
known molecular mass. Telomerase activity of M2 bound
FLAG-hTERT peaks in fraction No. A8 (Fig. 1F, TRAP
ELISA), which corresponds to an approximate molecular
mass of 680 kDa (Fig. 1F, upper panel). We could not
detect FLAG-hTERT in other peaks (fraction No. B11
and B12 were of molecular mass 250 kDa, No. C11 was of
molecular mass 150 kDa). We previously reported that
telomerase activity reconstituted in vitro using partially
purified FLAG-hTERT expressed in insect cells and
in vitro transcribed hTERC was resistant to GA, in
which Hsp90 was not detected (13). Similarly, we could
not detect Hsp90 in the M2-bound fraction and thus gel
filtration fractions (Fig. 1F, lower panel).
Fractionation of Insect Cell Lysate Expressing
Recombinant Telomerase—For initial purification trials,
we applied gel filtration chromatography. When the
soluble fraction of the lysate of insect cells expressing
FLAG-hTERT and hTERC-Rib was subjected to gel
filtration, FLAG-hTERT was distributed in two peaks,
of around 680 kDa (peak I) and 380 kDa (peak II) in
parallel with the distribution of telomerase activity
(Fig. 2A, upper panel, and B). FLAG-hTERT was not
distributed, and telomerase activity was not detected in
the fractions between peak I and peak II (fraction No.
B1, B2), confirming the specificity of distribution pattern.
Relative amount of hTERT in peak II to peak I was
0.44 (Fig. 2A, upper panel), and that of telomerase
activity was 0.84 which is higher than that of hTERT
(Fig. 2B). Anti-FLAG M2 antibody recognized two bands
in peak I and peak II (Fig. 2A, upper panel arrows and
asterisks indicated). The slower migrating band was
likely a cross-reacting protein of the insect cells, as it was
also detected in lysate of non-infected High5 cells
(Fig. 2A, lower panel arrows and asterisks indicated).
Furthermore, there was no telomerase activity in all
fractions of non-infected High5 cells (data not shown).
Most of the telomerase activity and FLAG-hTERT were
recovered when peak I fractions were subjected to anti-
FLAG M2-resin affinity chromatography in the presence
of 0.5% of Triton-X100, but telomerase activity and
FLAG-hTERT in peak II fractions could not be trapped
by affinity chromatography with anti-M2 resin in the
presence of 0.5% of Triton-X100 (Fig. 1F, data not
shown).
Distribution of hTERC in peak I and peak II
was quantified by real time RT-PCR using the
primer set for hTERC. The relative amount of
hTERC in peak II to peak I was 0.39 (Fig. 2C) that is
similar to the relative amount of hTERT measured by
western blot.
Next we analysed the distribution of endogenous
Hsp90. Hsp90 was exclusively distributed in peak II
but not in peak I (Fig. 2A, middle panel lanes 7–10).
Endogenous Hsp90 was found to be complexed
with FLAG-hTERT in peak II, as Hsp90 was recovered
in immunoprecipitates of anti-FLAG antibody in the
presence of 0.1% Triton-X100 (Fig. 2D, lane 4).
These results indicate that there are two different
complexes of the reconstituted telomerase in insect cells,
the complex without Hsp90 in peak I and the complex
with Hsp90 in peak II.
Characterization of Two Complexes Separated by
a Molecular Sieving in Insect Cells—To further
characterize two different telomerase complexes, we
tested whether GA affects two complexes in vivo.
FLAG-hTERT expressing insect cells was treated for
4 h with varying concentration of GA, and soluble
lysates were prepared and subjected to gel filtration.
Again, two complexes of FLAG-hTERT and telomerase
activity were observed at both peaks I and II. GA did
not affect the telomerase activity and the amount
of FLAG-hTERT in peak I treated with varying
concentration of GA (Fig. 3A). In contrast, incubation
with GA reduced the telomerase activity of peak II
fractions in a dose-dependent manner, accompanied by a
dose-dependent decrease of FLAG-hTERT in peak II
(Fig. 3B). GA had little effect on the recovery of Hsp90,
suggesting that the reduction in FLAG-hTERT was not
due to changes in Hsp90 levels (Fig. 3B). Similar results
were obtained by treatment with novobiocin (26), another
Hsp90 inhibitor.
These results suggest that telomerase activity in insect
cell extracts is found in two different fractions, one is
resistant, and the other is sensitive to Hsp90 inhibitors.
Fractionation of HeLa Cell Lysate—To examine
whether there were also two different telomerase com-
plexes in mammalian cells, HeLa cell lysate was
fractionated by molecular sieving. Two different hTERT
complexes were detected at around 680 kDa (peak I) and
400 kDa (peak II) (Fig. 4A, upper panel) that was slightly
larger than peak II of insect cells. Endogenous hTERT
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was much distributed in peak I (Fig. 4A, lanes 2–5).
Relative amount of hTERT in peak II to peak I was
0.39 that is almost similar to the relative amount of
hTERC measured by real time RT-PCR (0.32) (Fig. 4B,
real time RT-PCR). Distribution of telomerase activity of
the samples was quantified by TRAP ELISA, and relative
activity of telomerase activity in peak II to peak I was
0.85 (Fig. 4B, TRAP ELISA) that is almost similar to
the relative amount of telomerase activity in insect cells
(Fig. 2B). Similarly to insect cells, endogenous Hsp90
was distributed in peak II but not in peak I (Fig. 4, lower
panel). These results indicate that HeLa cells contain
two different hTERT complexes, one with and one
without Hsp90.
Fractionation of HeLa Cell Lysate Stably Expressing
FLAG-hTERT—Since most of the endogenous hTERT in
HeLa cells was distributed in peak I, whereas most of the
FLAG-hTERT in insect cells was also present in peak I
(Figs 2 and 4), we examined the distribution of
ectopically expressed hTERT in HeLa cells. HeLa cells
were stably transfected with the FLAG-hTERT expres-
sion virus (vBabe-puro-FLAG-hTERT), and the cell
lysate was fractionated by molecular sieving. We found
that the distribution of endogenous hTERT was similar
to that in HeLa cell lysate (Figs 4 and 5 upper panel);
furthermore, ectopically expressed FLAG-hTERT was
mainly distributed in peak I (Fig. 5, middle panel),
similar to finding in insect cells (Fig. 2). The distribution
patterns of endogenous hTERT, FLAG-hTERT and
hTERC were almost identical, and relative activity of
telomerase was also similar to that from HeLa cells (Figs
4B and 5B). As in the case of HeLa cell extracts, Hsp90
protein was detected only in peak II fractions (Fig. 5A,
lower panel lanes 7–10). Incubation of transfected total
cell lysate with anti-FLAG antibody immunoprecipitated
endogenous Hsp90 (Fig. 5C, lane 2). As observed for the
peak II complex in insect cells, endogenous Hsp90 was
similarly recovered in anti-FLAG immunoprecipitates
from the peak II complex in HeLa cells stably expressing
FLAG-hTERT (Fig. 5C, lane 4).
These results suggest that, similarly to the recombi-
nant telomerase reconstituted in insect cells, there are
also two different telomerase complexes in HeLa cells
stably expressing FLAG-hTERT, the complex without
Hsp90 in peak I and the complex with Hsp90 in peak II.
Characterization of the Complexes in HeLa Cells Stably
Expressing FLAG-hTERT—To determine whether the
hTERT complexes in HeLa cells stably expressing




































































































Fig. 2. Fractionation of the insect cell lysate expressing
recombinant telomerase. (A) High5 cells were infected
with recombinant baculoviruses BVKM-FLAG-hTERT and
BVKM-hTERC-Rib at MOI ratio of 2.0 : 4.0, and cell lysate was
fractionated on HiLoad 16/60 Superdex 200 pg gel filtration
columns in running buffer containing 200 mM NaCl and 0.1%
Triton-X100. The telomerase active peaks corresponded to
approximate molecular masses of 680 kDa (peak I) and
380 kDa (peak II). The fractions in peaks I and II were separated
by 8% SDS–PAGE and subjected to western blot analysis using
anti-FLAG M2 or anti-Hsp90 antibodies. Non-infected High5 cell
lysate was fractionated on the same column in the same running
buffer. Fraction samples were subjected to western blot analysis
using anti-FLAG M2 antibody. Lane 1, fraction No. A2; lane 2,
fraction No. A3; lane 3, fraction No. A4; lane 4, fraction No. A5;
lane 5, fraction No. A6; lane 6, fraction No. B1; lane 7, fraction
No. B2; lane 8, fraction No. B3; lane 9, fraction No. B4; lane 10,
fraction No. B5; and lane 11, fraction No. B6. The arrows and
asterisks indicate the band in insect cell lysates cross-reactive
with anti-FLAG M2 antibody. (B) Relative telomerase activity of
the fractions in peaks I and II was measured by TRAP ELISA.
(C) hTERC in peaks I and II was quantified by real time
RT-PCR (see ‘EXPERIMENTAL PROCEDURES’). Relative quantity of
fractions was expressed as a percentage of max concentration in
fraction No. A5. (D) Total lysate and peak I and peak II fractions
from High5 cells infected with the recombinant baculoviruses
BVKM-FLAG-hTERT and BVKM-hTERC-Rib were immunopre-
cipitated with anti-FLAG M2 resin. The bound proteins were
separated by 8% SDS–PAGE and subjected to western blot
analysis using anti-FLAG M2 or anti-Hsp90 antibodies as
indicated. Western blot analysis of total lysate is equal to 5%
of the input shown in lane 1 (¼ input). Lane 2, total lysate, IP;
anti-FLAG antibody; lane 3, peak I fractions, IP; anti-FLAG
antibody; and lane 4, peak II fractions, IP; anti-FLAG antibody.
The arrowsþ asterisks indicate the band in insect cell lysate
cross-reactive to anti-FLAG M2 antibody.
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FLAG-hTERT were sensitive to GA, HeLa cells stably
expressing FLAG-hTERT were treated for 4 h with
varying concentrations of GA. GA treatment reduced
the amounts of endogenous hTERT and FLAG-hTERT,
as well as telomerase activity, in a dose-dependent
manner (Fig. 6A). To determine whether GA-induced
down-regulation of hTERT was due to proteasome-
mediated degradation in vivo (22), we pre-treated HeLa
cells stably expressing FLAG-hTERT with MG132,
a proteasome inhibitor, for 2 h before GA treatment.
We found that the GA-induced reduction of both
endogenous hTERT and FLAG-hTERT was mostly
prevented by pre-treatment with MG132 (Fig. 6A,
lane5), indicating that GA reduction of endogenous
hTERT and FLAG-hTERT is due to preoteasome-
mediated degradation in vivo. Furthermore, the
GA-induced reduction pattern between endogenous
hTERT and FLAG-hTERT was almost identical. Under
these conditions, there was no change in the levels of
Hsp90 (Fig. 5A, lower panel), suggesting that the
reduction of hTERT is due to its degradation and not
due to changes in the Hsp90 level. In the absence of GA
treatment, incubation of HeLa cells with MG132 alone
did not cause a significant change in the levels of hTERT
expression relative to untreated controls (data not
shown). To confirm whether GA-induced degradation of
endogenous hTERT and FLAG-hTERT targeted the
hTERT complexed with Hsp90 in peak II, and whether
MG132 prevents the degradation of telomerase in peak
II, lysates of HeLa cells stably expressing FLAG-hTERT
cultured in medium with various concentrations of GA,
before or not before pre-treatment with MG132,
were fractionated by molecular sieving. GA and GA
plus MG132 had little effect on endogenous
hTERT, FLAG-hTERT and telomerase activity in peak
I (Fig. 6B). Otherwise GA decreased the amounts of
endogenous hTERT and FLAG-hTERT, and reduced
telomerase activity in the peak II fractions, and MG132
rescued the GA-induced down-regulation of endogenous
hTERT and FLAG-hTERT (Fig. 6C). The effect of GA
or GA plus MG132 on endogenous hTERT in HeLa cells
was the same as that of the HeLa cells stably expressing
FLAG-hTERT (data not shown). The result indicates
that telomerase complexed with Hsp90 in peak II is
sensitive to Hsp90 inhibitors, which induce degradation
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Fig. 3. Characterization of the two telomerase complexes
in insect cells. (A), (B) High5 cells infected with
the recombinant baculoviruses BVKM-FLAG-hTERT and
BVKM-hTERC-Rib were treated for 4 h with various GA
concentration indicated, and each cell lysate was fractionated
on HiLoad 16/60 Superdex 200 pg gel filtration columns in
running buffer containing 200 mM NaCl and 0.1% Triton-X100.
Peak I (A) and peak II (B) fractions were separated by 8%
SDS–PAGE and, subjected to western blotting using anti-FLAG
M2 or anti-Hsp90 antibodies as indicated. The
arrowsþasterisks indicate the band in insect cell lysate
cross-reactive to anti-FLAG M2 antibody. The fractions of
peak I and peak II (20 ng protein/each fraction) with varying
concentration of GA were subjected to TRAP and TRAP ELISA.
(A), (B) Lane 1, GA at 0 mg/ml; lane 2, GA at 50 mg/ml; lane 3, GA
at 75 mg/ml; lane 4, GA at 100 mg/ml.
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Fig. 4. Fractionation of HeLa cell lysate. (A) HeLa cell
lysate was fractionated on HiLoad 16/60 Superdex 200 pg gel
filtration columns in running buffer containing 200 mM NaCl
and 0.1% Triton-X100. The telomerase activity peaks were at
approximate molecular masses of 680 kDa (peak I) and 400 kDa
(peak II). The fractions in peaks I and II were separated by 8%
SDS–PAGE and subjected to Western blot analysis using anti-
TERT (2C4) or anti-Hsp90 antibodies as indicated. Lane 1,
fraction No. A2; lane 2, fraction No. A3; lane 3, fraction No. A4;
lane 4, fraction No. A5; lane 5, fraction No. A6; lane 6, fraction
No. B1; lane 7, fraction No. B2; lane 8, fraction No. B3; lane 9,
fraction No. B4; lane 10, fraction No. B5; lane 11, fraction No.
B6. (B) The quantification of hTERC in HeLa cells was
measured by real time RT-PCR as shown in Fig. 2C. Relative
telomerase activity of the fractions in peaks I and II (fraction
No. A2–B6) was measured by TRAP ELISA.
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of endogenous hTERT and FLAG-hTERT through a
proteasome-mediated pathway. Telomerase complex in
peak I was neither affected by GA nor by GA plus
MG132. These results with the lysate of HeLa cells
stably expressing FLAG-hTERT demonstrate that there
are two different complexes of telomerase with Hsp90
and without Hsp90, both of which retain telomerase
activity.
DISCUSSION
Telomerase activity is tightly regulated by several
control mechanisms (27). The limiting component of
telomerase, TERT, is under transcriptional and
post-transcriptional controls (28), and recruitment
of telomerase to the telomere is regulated in a cell-
cycle-dependent manner (29, 30). Modification and
degradation of hTERT are also involved in the assembly
of telomerase, subcellular trafficking and telomerase
activity itself (30). Since endogenous telomerase is
a limiting component in cells, it is difficult to
use biochemical approaches to gain insight into the
mechanisms of telomerase regulation without using
recombinant forms of telomerase. We therefore prepared
recombinant human telomerase reconstituted in insect
cells, as well as in vitro, from hTERT and hTERC.
Here we report two different complexes of recombinant
human telomerase in insect cells, as well as two
different complexes of endogenous and stably expressed
FLAG-tagged human telomerase in HeLa cells.
Distribution pattern of hTERT and hTERC in the
complex of 680 kDa and the complex of 380–400 kDa
from insect cells was almost similar to that from HeLa
cells. Moreover, the relative amount of telomerase
activity in the complex of 380–400 kDa to the
complex of 680 kDa between insect cells and HeLa
cells was almost identical (Figs 2, 4 and 5). Telomerase
activity of the complex of 380–400 kDa was sensitive
to Hsp90 inhibitors and was rather unstable in
proteasome-dependent pathway(s) due to the tight
complex of telomerase and Hsp90. In contrast,
telomerase activity of the complex of 680 kDa was free
from Hsp90, resistant to Hsp90 inhibitors, and rather
stable. The distribution and biochemical properties of
these complexes from HeLa cells are similar to those
from the insect cells. The mechanism to rescue the
telomere shortening by reverse transcription of telomere
repeats in eukaryotes is completely different from that in
insect cells in which non-long terminal repeat (non-LTR)
retrotransposons transpose on the chromosomal ends
(31–33). In fact, telomerase activity has been not
or barely detected in insect cells (31–33). Therefore,
the biochemical properties of the human telomerase
complexes reconstituted in vivo in insect cells in these
reports do not reflect or mimic the rescue mechanism of
chromosome ends in insect cells, but give an insight of
the possible complex formation of human telomerase
observed in insect cells that contains some ubiquitous
factors such as Hsp90. Molecular weight of Hsp90 is
90 kDa in mammalian cells, and 82 kDa in insect cells.
Since the complex of 380–400 kDa contains Hsp90
both in mammalian and insect cells, the slight difference
in the molecular masses in HeLa cells (400 kDa)
from that in insect cells (380 kDa) may be due to the
difference in molecular weight of Hsp90 in these cells.
Several different telomerase complexes of molecular
masses 550–1000 kDa have been reported. Wenz et al. (8)
showed that both in vitro reconstituted telomerase
and endogenous telomerase from HeLa cells formed a
complex of an approximate molecular mass of 600 kDa
(8). They demonstrated that this complex purified by
an affinity purification method, using a biotinylated
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Fig. 5. Fractionation of HeLa cell lysate stably expressing
FLAG-hTERT. (A) FLAG-hTERT was stably expressed in HeLa
cells, and the lysate was fractionated on HiLoad 16/60 Superdex
200 pg gel filtration columns in running buffer containing
200 mM NaCl and 0.1% Triton-X100. The telomerase activity
peaks were at approximate molecular masses of 680 kDa
(peak I) and 400 kDa (peak II). The fractions in peaks I and II
were separated by 8% SDS–PAGE and subjected to western blot
analysis using anti-TERT (2C4), anti-FLAG M2 or anti-Hsp90
antibodies as indicated. Lane 1, fraction No. A2; lane 2, fraction
No. A3; lane 3, fraction No. A4; lane 4, fraction No. A5; lane 5,
fraction No. A6; lane 6, fraction No. B1; lane 7, fraction No. B2;
lane 8, fraction No. B3; lane 9, fraction No. B4; lane 10, fraction
No. B5; lane 11, fraction No. B6. (B) The quantification of
hTERC in HeLa cell stably expressing FLAG-hTERT was
measured by real time RT-PCR. Relative telomerase activity of
the fractions in peaks I and II (fraction No. A2–B6) was
measured by TRAP ELISA. (C) Total lysate, peak I and peak II
fractions from HeLa cells stably expressing FLAG-hTERT were
immunoprecipitated with anti-FLAG M2 resin. The bound
proteins were separated by 8% SDS–PAGE and subjected to
western blot analysis using anti-FLAG M2 or anti-Hsp90
antibodies as indicated. Western blot analysis of total lysate is
equal to 5% of the input shown in lane 1 (¼ input). Lane 2,
total lysate, IP; anti-FLAG antibody, lane 3, peak I fractions, IP;
anti-FLAG antibody; and lane 4, peak II fractions, IP;
anti-FLAG antibody.
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Fig. 6. Characterization of the complexes in HeLa cells
stably expressing FLAG-hTERT. (A) HeLa cells
stably expressing FLAG-hTERT were treated for 4 h with the
GA concentration indicated; where indicated, cells were
pre-treated with MG132 at 10 mM for 2 h prior to treatment
with GA. Each lysate were separated by 8% SDS–PAGE and
then subjected to western blot analysis using anti-TERT (2C4),
anti-FLAG M2 or anti-Hsp90 antibodies as indicated.
The activity of each lysate was determined using the TRAP
assay and TRAP ELISA. Lane 1, GA at 0 mg/ml; lane 2, GA
at 50 mg/ml; lane 3, GA at 75 mg/ml; lane 4, GA at 100mg/ml;
lane 5, GA at 100mg/ml plus MG132 at 10 mM. (B), (C) HeLa
cells stably expressing FLAG-hTERT were treated with
100mg/ml GA for 4 h; where indicated, cells were pre-treated
with MG132 at 10 mM for 2 h before treatment with GA. Each
lysate were fractionated on HiLoad 16/60 Superdex 200 pg gel
filtration columns in running buffer containing 200 mM NaCl
and 0.1% Triton-X100. Peak I (B) and peak II (C) fractions were
separated by 8% SDS–PAGE and subjected to western blot
analysis using anti-TERT (2C4), anti-FLAG M2 or anti-Hsp90
antibodies as indicated, and analysed for telomerase activity
by the TRAP assay and TRAP ELISA. (B), (C) Lane 1, GA at
0 mg/ml; lane 2, GA at 100mg/ml; lane 3, GA at 100mg/ml plus
MG132 at 10 mM.
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oligonucleotide complementary to hTERC, was
telomerase dimer consisting of two hTERT (127 kDa)
and two hTERC (125 kDa) (8). Schnapp et al. (9) reported
that the affinity-purified telomerase complex had a
molecular mass of 550 kDa, although the telomerase
RNP in crude extracts had a molecular mass of 1000 kDa.
The telomerase complex of 680 kDa is similar in
molecular mass to the dimer form of telomerase reported
(8), although we do not have the direct evidence at
present. The telomerase complex of 680 kDa cannot be
converted to smaller molecular masses or monomer
form even in the presence of 2 M NaCl or 1%
Triton-X100 (data not shown). Consistent to the previous
report (9), telomerase complex in crude lysate of HeLa
cells apparently had a molecular mass of 1000 kDa
(data not shown). However, two separated complexes
(680 and 380–400 kDa) were observed instead of
1000 kDa in our conditions in contrast to a single
complex of 550 kDa (9). The discrepancy of telomerase
complexes among the previous and our reports may
be due to the different conditions including buffer
conditions and affinity purification methods. The
telomerase complex of 380–400 kDa is smaller than a
dimer form consisting of two hTERT and two hTERC
molecules, but may be a trimeric complex of hTERT,
hTERC and Hsp90.
As Holt et al. (20) firstly demonstrated, Hsp90
has been shown to be functionally a critical factor
for telomerase activity in vivo and in vitro with
transcription-coupled reconstituted telomerase (21),
although GA-sensitive property of telomerase activity
has not been reported with the purified reconstituted
telomerase (8, 9, 13). Here we show that the telomerase
complex with Hsp90 in the complex of 380–400 kDa is not
only sensitive to GA, but also unstable during incubation.
This property is evidently due to proteolytic degradation
via proteasome pathway(s), since the proteasome
inhibitors prevented the degradation of endogenous
hTERT and FLAG-hTERT in the complex of
380–400 kDa. Hsp90 functions in a variety of aspects
(34–36), and Hsp90 inhibitors prevent the degradation of
some client proteins, and facilitate the degradation of
other client proteins (22, 37). With telomerase, Hsp90
may function in a way distinct from its role as chaperone
that serves premature state of client proteins into
mature proteins. Keppler et al. (38) suggested two
different roles for Hsp90: one in telomerase assembly
and another in primer loading. They reported that a
lower concentration of GA (IC50 of 8.4 mM) inhibited the
formation of active telomerase if present during the
assembly, but that a higher concentration (IC50 of
53 mM) was required to inhibit telomerase if added after
the assembly. The different effects of GA on the two
complexes in this report were observed at the GA
concentration that could inhibit both roles of Hsp90
(38). Under these conditions, any telomere shortening of
the GA-treated cells was not observed (data not shown).
It is noteworthy that anti-FLAG M2-resin affinity
chromatography can purify FLAG-tagged hTERT in
the complex of 680 kDa but not that in the complex of
380–400 kDa in the presence of 0.5% Triton-X100
(‘EXPERIMENTAL PROCEDURES’), although the
latter can be recovered in the immunoprecipitates
with anti-FLAG M2 antibody in 0.1% of Triton-X100.
The availability of the N-terminal-tagged FLAG in the
complex of 380–400 kDa was actually affected by
the different concentrations of Triton-X100, since ectopi-
cally expressed N-terminal-tagged hTERT functions have
been reported to be biologically active in telomerase (39,
40). The anti-FLAG M2 antibody could immunoprecipi-
tate FLAG-hTERT and telomerase activity of the com-
plex of 380–400 kDa only in the presence of 0.1% Triton-
X100, whereas it could recover FLAG-hTERT and
telomerase activity of the complex of 680 kDa at both
concentrations. The result suggests that N-terminal of
FLAG-hTERT in the complex of 380–400 kDa is not
available to the antibody due to some conformation
change or dissociation of its interacting partner(s)
induced in the high concentration of the detergent.
As Hsp90 is a critical factor for telomerase activity
in vivo (20, 21, 41), the complex of 380–400 kDa seems to
be biologically functional for telomerase activity in vivo.
There are several possibilities on biological roles of the
complex of 680 kDa. First, the telomerase complex
of 680 kDa may be a precursor form of the complex of
380–400 kDa. This seems unlikely since cycloheximide
treatment, which blocks de novo synthesis of hTERT and
thus of telomerase, did not affect the distribution pattern
of hTERT in the two complexes (data not shown). Second,
excess telomerase may be reserved in a different state
(the complex of 680 kDa) from the working complex in
the complex of 380–400 kDa. This possibility may be
consistent with the result that more than half of
telomerase activity is sensitive to GA in vivo, although
the complex of 680 kDa is the major one in the lysate.
Third, the complex of 680 kDa may be a working enzyme
not for telomere synthesis but for another function
of telomerase that may be required for DNA damage
responses (42). These possibilities remains to be exam-
ined in future studies. This is the first demonstration of
two distinct active complexes of human telomerase that
may contribute to further understanding of several
aspects of function(s) and regulation of telomerase.
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